PulseAI, which develops cardiac diagnostics technology, has closed a seed funding round led by Innovation Ulster Limited, with participation from The Mortara Group and The Francis Crick Institute. The investment will enable it to scale deployment of its ECG technology and advance its pathway through US FDA 510(k) clearance.
Electrocardiograms are widely used as a frontline diagnostic tool, but interpretation often relies on specialist training and manual analysis. This can lead to delays, diagnostic variability, and missed opportunities for early intervention.
PulseAI’s ECG platform is designed to deliver clinical decision support in both primary and acute care settings, aiming to improve the accuracy and consistency of cardiac diagnostics and broaden access across healthcare systems.
As part of the round, Dr Justin Mortara will join PulseAI as Chair of the Board, strengthening its alignment with organisations active in cardiac monitoring, diagnostics, and hospital systems.
The funding will support regulatory advancement including FDA 510(k), further clinical validation across diverse populations and care settings, productisation for enterprise and OEM integration, and expansion of partnerships with device manufacturers and hospital networks.
